DWC202312

DWC202312 is an investigational drug developed by Daewoong Pharmaceutical, currently being studied in a bioequivalence clinical trial comparing its pharmacokinetics and safety to DWJ1567 in healthy adult volunteers. The study is designed as a randomized, open-label, oral, single-dose, four-way crossover trial. The primary endpoints are maximum plasma concentration (Cmax) and area under the curve to last measurable concentration (AUCt), with secondary endpoints including AUCinf, Tmax, and half-life (t1/2). As of now, there is no publicly available information regarding the specific mechanism of action or therapeutic indication for DWC202312. The drug appears to be at an early stage of development focused on establishing bioequivalence rather than targeting a specific disease[1][3][5].